Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

4(40.0%)

Phase 1

4(40.0%)

Phase 3

2(20.0%)

10Total

Phase 2(4)

Phase 1(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07116746Phase 2Recruiting

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

Role: lead

NCT06846515Phase 3Active Not Recruiting

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Role: lead

NCT06439602Phase 3Active Not Recruiting

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Role: lead

NCT05253833Phase 2Completed

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

Role: lead

NCT05119686Phase 2Completed

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

Role: lead

NCT04646889Phase 1Completed

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

Role: lead

NCT04155918Phase 2Completed

Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

Role: lead

NCT04508426Phase 1Completed

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

Role: lead

NCT04347005Phase 1Completed

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

Role: lead

NCT04314986Phase 1Completed

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

Role: lead

All 10 trials loaded